Akers Biosciences is committed to addressing global health challenges. Established in 1989, Akers has accumulated over three decades of achievement in the health diagnostic sector through the development of exclusive, in vitro diagnostic technologies. In March 2020, as part of their commitment, Akers revealed a strategic alliance with Premas Biotech with a primary focus on innovative vaccine candidates. The current pandemic presents an opportunity for the company to contribute to the healthcare sector, paving the way for its next phase of expansion.